NCT05704881 Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations
| NCT ID | NCT05704881 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Grenoble |
| Condition | Pulmonary Disease, Chronic Obstructive |
| Study Type | OBSERVATIONAL |
| Enrollment | 240 participants |
| Start Date | 2023-03-03 |
| Primary Completion | 2026-09-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 240 participants in total. It began in 2023-03-03 with a primary completion date of 2026-09-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.
Eligibility Criteria
Inclusion Criteria: * All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family * Male or female≥18 years old who did not oppose to participating in the study Exclusion Criteria: * Hypotension (SBP \< 90 mmHg or MBP \< 65 mmHg) * Patient already included in the study during a previous visit to the emergency department * Patient already ventilated with invasive or NIV during admission to the emergency department * COPD exacerbation rejected after medical and additional examinations * Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness * Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
Contact & Investigator
Damien VIGLINO, Prof. MD PhD
STUDY DIRECTOR
University Hospital, Grenoble
Frequently Asked Questions
Who can join the NCT05704881 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Disease, Chronic Obstructive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05704881 currently recruiting?
Yes, NCT05704881 is actively recruiting participants. Contact the research team at nsegond@chu-grenoble.fr for enrollment information.
Where is the NCT05704881 trial being conducted?
This trial is being conducted at Grenoble, France, Lyon, France.
Who is sponsoring the NCT05704881 clinical trial?
NCT05704881 is sponsored by University Hospital, Grenoble. The principal investigator is Damien VIGLINO, Prof. MD PhD at University Hospital, Grenoble. The trial plans to enroll 240 participants.